Taiwan Bio Therapeutics Co., Ltd
Taiwan Bio Therapeutics Co., Ltd., regenerative medicine company, focuses on the development of new cell medicines. It offers medicines for degenerative diseases, cardiovascular diseases, diabetes complications, and autoimmune diseases. The company was founded in 2014 and is based in Taipei City, Taiwan.
Taiwan Bio Therapeutics Co., Ltd (6892) - Net Assets
Latest net assets as of June 2025: NT$898.79 Million TWD
Based on the latest financial reports, Taiwan Bio Therapeutics Co., Ltd (6892) has net assets worth NT$898.79 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.29 Billion) and total liabilities (NT$391.88 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$898.79 Million |
| % of Total Assets | 69.64% |
| Annual Growth Rate | 100.76% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 98.6 |
Taiwan Bio Therapeutics Co., Ltd - Net Assets Trend (2020–2024)
This chart illustrates how Taiwan Bio Therapeutics Co., Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Taiwan Bio Therapeutics Co., Ltd (2020–2024)
The table below shows the annual net assets of Taiwan Bio Therapeutics Co., Ltd from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.09 Billion | +77.96% |
| 2023-12-31 | NT$613.29 Million | +16.41% |
| 2022-12-31 | NT$526.83 Million | +105.39% |
| 2021-12-31 | NT$256.50 Million | +281.79% |
| 2020-12-31 | NT$67.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Taiwan Bio Therapeutics Co., Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 26984000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$844.83 Million | 77.41% |
| Other Components | NT$601.81 Million | 55.14% |
| Total Equity | NT$1.09 Billion | 100.00% |
Taiwan Bio Therapeutics Co., Ltd Competitors by Market Cap
The table below lists competitors of Taiwan Bio Therapeutics Co., Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Alternative Investment Trust
AU:AIQ
|
$8.06K |
|
United Royale Holdings Corp
OTCQB:URYL
|
$8.06K |
|
Fingerprint Cards AB (publ)
OTCGREY:FGRRF
|
$8.06K |
|
Yield10 Bioscience Inc
NASDAQ:YTEN
|
$8.06K |
|
CSAN3F
SA:CSAN3F
|
$8.05K |
|
Huatai Tianjin Huatai Securities Assets Management- Jiangsu Traffic Control Reit
SHG:508066
|
$8.05K |
|
AUST AGRICULTURAL
MU:AY5
|
$8.05K |
|
Middle East Glass Manufacturing
EGX:MEGM
|
$8.05K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Taiwan Bio Therapeutics Co., Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 613,291,000 to 1,091,389,000, a change of 478,098,000 (78.0%).
- Net loss of 351,802,000 reduced equity.
- New share issuances of 801,199,000 increased equity.
- Other factors increased equity by 28,701,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-351.80 Million | -32.23% |
| Share Issuances | NT$801.20 Million | +73.41% |
| Other Changes | NT$28.70 Million | +2.63% |
| Total Change | NT$- | 77.96% |
Book Value vs Market Value Analysis
This analysis compares Taiwan Bio Therapeutics Co., Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.89x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.96x to 1.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | NT$6.99 | NT$27.65 | x |
| 2021-12-31 | NT$8.63 | NT$27.65 | x |
| 2022-12-31 | NT$10.59 | NT$27.65 | x |
| 2023-12-31 | NT$10.74 | NT$27.65 | x |
| 2024-12-31 | NT$14.65 | NT$27.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Taiwan Bio Therapeutics Co., Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -334.75%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.35x
- Recent ROE (-32.23%) is above the historical average (-38.16%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -52.15% | 0.00% | 0.00x | 2.97x | NT$-41.76 Million |
| 2021 | -35.17% | -332.13% | 0.05x | 2.30x | NT$-115.85 Million |
| 2022 | -35.79% | -421.41% | 0.05x | 1.65x | NT$-241.25 Million |
| 2023 | -35.47% | -254.49% | 0.09x | 1.54x | NT$-278.84 Million |
| 2024 | -32.23% | -334.75% | 0.07x | 1.35x | NT$-460.94 Million |
Industry Comparison
This section compares Taiwan Bio Therapeutics Co., Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Taiwan Bio Therapeutics Co., Ltd (6892) | NT$898.79 Million | -52.15% | 0.44x | $8.06K |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |